Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

NCT00984282 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00984282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00984282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
October 15, 2009
Completion date
August 30, 2017
Enrollment
417 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid neoplasms